Minimizing individual variations in arterial enhancement on coronary CT angiographs using "contrast enhancement optimizer": a prospective randomized single-center study

Eur Radiol. 2019 Jun;29(6):2998-3005. doi: 10.1007/s00330-018-5823-2. Epub 2018 Nov 12.

Abstract

Objectives: To investigate the clinical utility of our newly developed contrast enhancement optimizer (CEO) software for coronary CT angiography (CCTA).

Methods: We randomly assigned 295 patients (168 males, 127 females, median age 71 years) undergoing CCTA to one of two contrast media injection protocols. Group A (n = 150) was injected with a CEO-selected iodine dose based on patient factors. In group B (n = 145), we used our standard protocol (245 mg I/kg). We recorded the CT number in the ascending aorta and determined whether the CT number was equivalent in groups A and B. For the equivalence test, we adopted 75 Hounsfield units (HU) as the equivalence margin. The standard deviation in the CT number and the rate of patients with an acceptable CT number were compared using the F test and the chi-square test, respectively.

Results: The iodine dose in group A was significantly smaller than that in group B (235.7 vs. 253.6 mg I/kg, p < 0.001). The CT number of the ascending aorta was 428.6 ± 55.5 HU in group A and 436.1 ± 68.7 HU in group B; the 95% confidence interval for the difference between the groups was -4.3 HU to 16.9 HU and within the range of the predetermined equivalence margins. In group A, the variance was significantly smaller than that in group B (p = 0.009). The number of patients with an acceptable CT number was significantly higher in group A than in group B (84.7% vs. 71.7%, p = 0.007).

Conclusions: The use of our CEO for CCTA studies yielded optimal aortic contrast enhancement in significantly more patients than the standard protocol based on the body weight.

Key points: • With our contrast enhancement optimizer (CEO) software, optimal and stable aortic enhancement can be obtained on coronary CT angiography scans irrespective of patient factors. • Management of contrast media becomes more appropriate by the CEO software. • The CEO software can control contrast enhancement at different tube voltage levels.

Keywords: Cardiac imaging techniques; Cardiac output; Computed tomography angiography; Contrast media; Diagnostic imaging.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Computed Tomography Angiography / methods*
  • Contrast Media / pharmacology
  • Coronary Angiography / methods*
  • Coronary Artery Disease / diagnosis*
  • Coronary Vessels / diagnostic imaging*
  • Female
  • Humans
  • Iopamidol / analogs & derivatives*
  • Iopamidol / pharmacology
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Contrast Media
  • iomeprol
  • Iopamidol